Last 48 quarters of trend data · Healthcare · Cell & Gene Therapy
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 7.29 | 3.92 | 62.71 | 54.78 | 72.56 | 61.96 | — | — | — | — | — | — | — | 38.50 | — | — | — | — | — | — | — |
| — | -93.7% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 3.83 | 5.84 | 8.06 | 9.80 | 12.35 | 12.54 | 13.66 | 14.73 | 12.75 | 17.65 | 11.67 | 9.53 | 13.67 | 7.75 | 18.57 | 19.47 | 21.86 | 23.13 | 19.61 | 23.05 | 19.64 |
| — | -53.4% | -41.0% | -33.5% | -3.2% | -29.0% | +17.1% | +54.5% | -6.7% | +127.8% | -37.2% | -51.0% | -37.5% | -66.5% | -5.3% | -15.5% | +11.3% | -22.8% | -13.4% | -1.0% | -15.0% | |
| P/B Ratio | 24.54 | 9.45 | 30.73 | 42.53 | 68.67 | 267.77 | 168.75 | 303.33 | 451.03 | 1093.10 | — | — | — | — | — | — | — | — | 100.16 | 49.00 | 34.53 |
| — | -96.5% | -81.8% | -86.0% | -84.8% | -75.5% | — | — | — | — | — | — | — | — | — | — | — | — | +328.1% | +174.6% | +132.2% | |
| P/FCF | 38.35 | 31.40 | 256.00 | 234.92 | 96.59 | 50.03 | 75.82 | — | — | 223.75 | 66.29 | — | — | 16.99 | — | — | — | — | — | — | — |
| — | -37.2% | +237.7% | — | — | -77.6% | +14.4% | — | — | +1217.2% | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | 18.22 | 23.29 | 41.96 | 40.13 | 92.64 | 40.89 | — | 271.67 | — | — | 122.34 | — | — | 25.90 | — | — | — | — | — | — | — |
| — | -43.0% | — | -85.2% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | 37.53 | 22.07 | 44.53 | 38.92 | 46.32 | 55.10 | 2172.13 | — | — | — | 352.31 | — | — | 32.39 | — | — | — | — | — | — | — |
| — | -59.9% | -97.9% | — | — | — | +516.5% | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 81.8% | 75.2% | 76.9% | 81.9% | 75.6% | 84.2% | 81.5% | 88.0% | 82.7% | 82.9% | 89.6% | 86.7% | 80.5% | 88.8% | 73.2% | 82.8% | 84.7% | 84.4% | 81.8% | 83.3% | 85.4% |
| — | -10.7% | -5.7% | -7.0% | -8.6% | +1.6% | -9.0% | +1.6% | +2.7% | -6.7% | +22.4% | +4.6% | -5.0% | +5.1% | -10.5% | -0.6% | -0.9% | +2.2% | -0.7% | +1.0% | -0.6% | |
| Operating Margin | 13.5% | 23.7% | 17.9% | 23.0% | 12.0% | 29.5% | -2.1% | 3.0% | -17.7% | -15.4% | 7.4% | -8.8% | -26.5% | 28.5% | -72.1% | -46.9% | -56.3% | -97.6% | -85.3% | -68.8% | -75.3% |
| — | -19.5% | +956.3% | +656.5% | +167.7% | +291.9% | -128.4% | +134.6% | +33.0% | -153.9% | +110.2% | +81.3% | +53.0% | +129.2% | +15.4% | +31.8% | +25.2% | -0.8% | -28.7% | +34.4% | +36.6% | |
| Net Margin | 8.4% | 148.6% | 12.7% | 17.6% | 17.0% | 20.1% | -8.6% | -9.7% | -14.1% | -22.3% | -2.6% | -13.3% | -31.4% | 19.7% | -86.6% | -54.5% | -61.9% | -153.6% | -123.4% | -112.7% | -100.0% |
| — | +639.4% | +248.7% | +282.4% | +220.3% | +190.3% | -234.7% | +27.5% | +55.0% | -213.1% | +97.0% | +75.5% | +49.4% | +112.8% | +29.8% | +51.6% | +38.1% | -40.9% | -43.6% | +0.1% | +32.9% |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 73.3% | 87.4% | 13.5% | 22.1% | 36.4% | 103.6% | -36.2% | -63.0% | -168.5% | -761.9% | — | — | — | — | — | — | — | -748.9% | -96.1% | -48.6% | -38.5% |
| — | -15.7% | +137.4% | +135.1% | +121.6% | +113.6% | — | — | — | — | — | — | — | — | — | — | — | -2846.5% | -351.2% | -135.6% | -76.2% | |
| ROA | 6.8% | 32.0% | 3.1% | 4.1% | 3.8% | 5.3% | -1.5% | -1.4% | -2.0% | -2.7% | -0.4% | -1.7% | -3.6% | 4.1% | -8.1% | -5.0% | -5.9% | -11.8% | -8.2% | -6.8% | -7.3% |
| — | +499.8% | +303.9% | +400.1% | +291.4% | +296.3% | -250.1% | +21.1% | +44.8% | -166.6% | +94.7% | +65.7% | +38.6% | +134.5% | +0.9% | +26.1% | +19.3% | -101.8% | -46.4% | -13.0% | -0.1% | |
| ROIC | 93.2% | 12.9% | 22.4% | 38.5% | 42.7% | 113.6% | -2.9% | 3.4% | -25.0% | -20.4% | 3.4% | -1.9% | -9.9% | 89.5% | -54.1% | -32.8% | -59.1% | -50.0% | -19.8% | -13.5% | -24.6% |
| — | -88.7% | +865.9% | +1026.1% | +270.9% | +657.6% | -184.8% | +279.9% | -151.9% | -122.8% | +106.4% | +94.2% | +83.2% | +279.0% | -173.6% | -142.9% | -140.6% | -136.8% | -74.4% | -1.9% | -76.1% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.62 | 0.35 | 0.94 | 1.18 | 1.62 | 5.59 | 5.18 | 11.28 | 19.32 | 40.24 | — | — | — | — | — | — | — | — | 5.63 | 2.48 | 1.70 |
| — | -93.7% | -81.9% | -89.5% | -91.6% | -86.1% | — | — | — | — | — | — | — | — | — | — | — | — | +531.2% | +343.2% | +230.7% | |
| Debt / EBITDA | 2.29 | 3.50 | 5.17 | 4.51 | 8.80 | 3.43 | — | 40.07 | — | — | 20.49 | — | — | 5.76 | — | — | — | — | — | — | — |
| — | +2.2% | — | -88.7% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 2.76 | 2.48 | 3.05 | 3.13 | 2.76 | 2.54 | 2.80 | 3.04 | 2.78 | 2.75 | 3.01 | 3.17 | 3.08 | 3.14 | 3.20 | 3.77 | 3.51 | 3.48 | 3.76 | 4.27 | 4.04 |
| — | -2.5% | +9.1% | +2.9% | -0.6% | -7.6% | -6.8% | -4.3% | -9.9% | -12.5% | -6.1% | -15.9% | -12.1% | -9.7% | -14.8% | -11.7% | -13.2% | -20.5% | -23.5% | +7.3% | -9.6% | |
| Quick Ratio | 2.71 | 2.43 | 2.99 | 3.06 | 2.71 | 2.49 | 2.75 | 2.98 | 2.71 | 2.69 | 2.93 | 3.07 | 2.99 | 3.04 | 3.07 | 3.58 | 3.34 | 3.33 | 3.62 | 4.14 | 3.91 |
| — | -2.6% | +8.9% | +2.9% | -0.2% | -7.2% | -6.2% | -3.1% | -9.3% | -11.7% | -4.8% | -14.1% | -10.4% | -8.7% | -15.2% | -13.7% | -14.7% | -21.0% | -23.9% | +8.1% | -9.8% | |
| Interest Coverage | 2.28 | 4.51 | 2.82 | 4.20 | 2.25 | 6.38 | 0.12 | -0.08 | -3.98 | -2.16 | 0.66 | -0.80 | -3.39 | 5.88 | -8.13 | -4.95 | -5.92 | -8.88 | -5.45 | -4.65 | -6.07 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ALNY stock.
Alnylam Pharmaceuticals, Inc.'s current P/E is 7.3x. The average P/E over the last 4 quarters is 48.5x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Alnylam Pharmaceuticals, Inc.'s current operating margin is 13.5%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Alnylam Pharmaceuticals, Inc.'s business trajectory between earnings reports.